Volume 1: Issue 2

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Michael McGoon, MD, SLC Chair, Pulmonary Hypertension Clinic/Mayo Clinic, Rochester, Minnesota
Robyn Barst, MD, SLC Vice-Chair, Columbia Presbyterian Medical Center, Babies Hospital, New York, New York
David B. Badesch, MD, Chair, SLC Nominations Committee, University of Colorado Health Sciences Center, Denver, Colorado
Joy Beckmann, RN, MSN, Pulmonary Hypertension Program, Harbor-UCLA Medical Center, Torrance, California
C. Gregory Elliott, MD, Chair, SLC Publications Committee, LDS Hospital, University of Utah School of Medicine, Salt

Often unsuspected and underappreciated, pulmonary arterial hypertension in some forms of scleroderma is much like primary pulmonary hypertension; the cause of the dyspnea and associated symptoms frequently eludes diagnosis until very late in the disease.

Unfortunately, by that time, pulmonary hypertension may have reached an advanced stage less amenable to treatment. Although many patients with collagen vascular disease are considered at high risk for inflammatory pulmonary involvement, the disease process is often insidious and appropriate evaluation, including pulmonary function tests, echocardiography, and right-heart catheterization, may not be ordered when the benefit of treatment might be more substantial. One of the

Vallerie McLaughlin, MD, Associate Professor of Medicine, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois, conducted this roundtable discussion. The panel included James R. Seibold, MD, Professor and Director, UMDNJ Scleroderma Program. New Brunswick New Jersey; David B. Badesch, MD, Professor of Medicine and Clinical Director, Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver, Colorado; and Virginia Steen, MD, Professor of Medicine, Georgetown University Medical Center, Washington, DC.

The Scientific Leadership Council of the Pulmonary Hypertension Association

Bridging the Gap Between Specialists With Insights From an Expert Panel

Driven to Find Cure for PH, Brundage Leads New Quest for Breakthrough in Therapy

Scleroderma-Associated Pulmonary Hypertension: Who's at Risk and Why

Introduction

Cardiac Catheterization in Pulmonary Arterial Hypertension: A Guide to Proper Use

Screening for PAH in Scleroderma: Identifying Hallmarks of the Disease and Optimal Treatment Strategies

Racial and Ethnic Equity in Pulmonary Arterial Hypertension Clinical Trials

Multiomics Integration for Identifying Treatment Targets, Drug Development, and Diagnostic Designs in PAH

Tyrosine Kinase Inhibitors for Treatment of Pulmonary Arterial Hypertension

Full Issue PDF

Editor’s Memo